{
  "id": 3615,
  "text": "1606.Katsumata, N., et al.Phase II study of S1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.Ann Oncol 22, 1353-1357 (2011).1607.Garcia, A.A., et al.Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1606.Katsumata, N., et al.Phase II study of S1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.Ann Oncol 22, 1353-1357 (2011).1607.Garcia, A.A., et al.Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "使用口服氟尿嘧啶类药物如S1或卡培他滨治疗晚期或持续复发的宫颈癌已在临床试验中进行了研究。这些研究表明，这类药物在宫颈鳞状细胞癌治疗中可以取得一定的疗效。患者通常对治疗耐受良好，并且这种疗法可能为那些已经接受过标准治疗但仍出现复发的患者提供额外的选择。此外，研究也在探讨这些药物在不同治疗阶段结合其他疗法的潜力，以进一步提升疗效。在使用氟尿嘧啶治疗时，仍需关注可能出现的副作用，并根据患者具体情况进行调整，以确保疗效最大化与安全性。",
  "query": "宫颈鳞状细胞癌患者在晚期或持续复发阶段，使用口服氟尿嘧啶进行临床治疗会有怎样的效果？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 宫颈鳞状细胞癌患者在晚期或持续复发阶段，使用口服氟尿嘧啶进行临床治疗会有怎样的效果？\n\n<reference text>: 1606.Katsumata, N., et al.Phase II study of S1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.Ann Oncol 22, 1353-1357 (2011).1607.Garcia, A.A., et al.Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "使用口服氟尿嘧啶类药物如S1或卡培他滨治疗晚期或持续复发的宫颈癌已在临床试验中进行了研究。这些研究表明，这类药物在宫颈鳞状细胞癌治疗中可以取得一定的疗效。患者通常对治疗耐受良好，并且这种疗法可能为那些已经接受过标准治疗但仍出现复发的患者提供额外的选择。此外，研究也在探讨这些药物在不同治疗阶段结合其他疗法的潜力，以进一步提升疗效。在使用氟尿嘧啶治疗时，仍需关注可能出现的副作用，并根据患者具体情况进行调整，以确保疗效最大化与安全性。"
}